A practical reference on MC1R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-23 and is reviewed periodically as new material appears.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
In molecular biology, initiation factors are proteins that bind to the small subunit of the ribosome during the initiation of translation, a part of protein biosynthesis. Initiation factors can interact with repressors to slow down or prevent translation. They have the ability to interact with activators to help them start or increase the rate of translation. In bacteria, they are simply called IFs (i.e.., IF1, IF2, & IF3) and in eukaryotes they are known as eIFs (i.e.., eIF1, eIF2, eIF3). Translation initiation is sometimes described as three step process which initiation factors help to carry out. First, the tRNA carrying a methionine amino acid binds to the small subunit of ribosome, then binds to the mRNA, and finally joins together with the large subunit of ribosome. The initiation factors that help with this process each have different roles and structures.
{\displaystyle {\begin{aligned}\theta :\ &\rho \left({\partial _{t}u_{\theta }}+u_{r}{\partial _{r}u_{\theta }}+{\frac {u_{\varphi }}{r\sin \theta }}{\partial _{\varphi }u_{\theta }}+{\frac {u_{\theta }}{r}}{\partial _{\theta }u_{\theta }}+{\frac {u_{r}u_{\theta }-u_{\varphi }^{2}\cot \theta }{r}}\right)\\&\quad =-{\frac {1}{r}}{\partial _{\theta }p}\\&\qquad +\mu \left({\frac {1}{r^{2}}}\partial _{r}\left(r^{2}{\partial _{r}u_{\theta }}\right)+{\frac {1}{r^{2}\sin ^{2}\theta }}{\partial _{\varphi }^{2}u_{\theta }}+{\frac {1}{r^{2}\sin \theta }}\partial _{\theta }\left(\sin \theta {\partial _{\theta }u_{\theta }}\right)+{\frac {2}{r^{2}}}{\partial _{\theta }u_{r}}-{\frac {u_{\theta }+2\cos \theta {\partial _{\varphi }u_{\varphi }}}{r^{2}\sin ^{2}\theta }}\right)\\&\qquad +{\frac {1}{3}}\mu {\frac {1}{r}}\partial _{\theta }\left({\frac {1}{r^{2}}}\partial _{r}\left(r^{2}u_{r}\right)+{\frac {1}{r\sin \theta }}\partial _{\theta }\left(u_{\theta }\sin \theta \right)+{\frac {1}{r\sin \theta }}{\partial _{\varphi }u_{\varphi }}\right)\\&\qquad +\rho g_{\theta }.\end{aligned}}}
The Foreign Ministry also confirmed that no Malaysians in the country were affected by the strikes, stating that the situation is closely monitored and actively obtaining updates to ensure safety of Malaysians. Prime Minister Anwar Ibrahim described the operation on Facebook as "unusual in scope and nature" as well as constitutes a "clear violation of international law and amounts to an unlawful use of force against a sovereign state". Oman: The Ministry of Foreign Affairs stated that it respects state sovereignty and independence and fully supports international law. In order to avoid escalation and bring about reconciliation, it urged all sides to use moderation and promote communication. Pakistan: The Ministry of Foreign Affairs stated that it attaches "great importance" to the wellbeing of the Venezuelan people, and urges the need for restraint and de-escalation in line with the principles of the Charter of the United Nations. It added that it is engaged with the situation on the ground to ensure the safety and security of Pakistanis in Venezuela. Philippines: The Department of Foreign Affairs stated that it is monitoring the situation in Venezuela and urged "concerned parties to resolve disputes through peaceful means, and to exercise restraint to prevent escalation of conflict". It said the Philippine Embassy in Bogotá, the non-resident mission for Venezuela, had "issued a travel and safety advisory to Filipinos in Venezuela" and was prepared to provide assistance.
Sources: en.wikipedia.org
In DPI formulations the micronized active is then blended with larger (typically 50–200 μm) carrier particles, most commonly α-lactose monohydrate, from which the drug detaches on inhalation. The high surface energy and amorphous content generated by jet milling can cause inhalation powders to cohere or to recrystallize on storage, altering aerosol performance over time. Manufacturers therefore typically condition micronized inhalation actives for example by controlled exposure to humidity or solvent vapour to relax surface disorder before formulation. Carrier-based dry powder inhaler formulations require an API with a stable crystalline structure that can withstand the stress of milling, whereas spray drying can yield amorphous particles with faster dissolution than crystalline micronized forms.
Alcohol or drug intoxication Cardiac arrhythmia Valvular heart disease Postprandial syndrome Hyperthyroidism Pheochromocytoma Post-gastric bypass hypoglycemia Generalized anxiety disorder Surreptitious insulin use Lab or blood draw error (lack of antiglycolytic agent in collection tube or during processing)
==== Binge eating ==== Estrogen may play a role in suppressing binge eating. Hormone replacement therapy using estrogen may be a possible treatment for binge eating behaviors in females. Estrogen replacement has been shown to suppress binge eating behaviors in female mice. The mechanism by which estrogen replacement inhibits binge-like eating involves the replacement of serotonin (5-HT) neurons. Women exhibiting binge eating behaviors are found to have increased brain uptake of neuron 5-HT, and therefore less of the neurotransmitter serotonin in the cerebrospinal fluid. Estrogen works to activate 5-HT neurons, leading to suppression of binge like eating behaviors. It is also suggested that there is an interaction between hormone levels and eating at different points in the female menstrual cycle. Research has predicted increased emotional eating during hormonal flux, which is characterized by high progesterone and estradiol levels that occur during the mid-luteal phase. It is hypothesized that these changes occur due to brain changes across the menstrual cycle that are likely a genomic effect of hormones. These effects produce menstrual cycle changes, which result in hormone release leading to behavioral changes, notably binge and emotional eating. These occur especially prominently among women who are genetically vulnerable to binge eating phenotypes. Binge eating is associated with decreased estradiol and increased progesterone. Klump et al.
=== CAM2038 - drug addiction === CAM2038 represents a new treatment concept for opiate addiction based on the well-documented anti-addiction therapeutic buprenorphine. CAM2038 is developed as a sustained release injection depot.
Sources: en.wikipedia.org
== Measurement of renal clearance == Renal clearance can be measured with a timed collection of urine and an analysis of its composition with the aid of the following equation (which follows directly from the derivation of (10b)):
However, enobosarm did not successfully increase muscle strength in these phase 3 trials. In any case, it has been suggested that the study designs and physical function outcomes in such trials may have been flawed. The increases in lean body mass that have been seen with employed doses of enobosarm in clinical trials are very modest compared to those produced with supraphysiological doses of testosterone over similar timeframes (e.g., 0.5–1.5 kg with enobosarm versus 5–8 kg with 300–600 mg/week intramuscular testosterone enanthate in healthy young men). The effects of higher doses of enobosarm (9–18 mg/day) on lean body mass and muscle strength are also being evaluated in women with breast cancer. There is some evidence that women may be more sensitive to lean body mass increases with SARMs, specifically GSK-2881078 but potentially also others like enobosarm, than men. In addition to its mixed agonist–antagonist activity at the AR, enobosarm is likely to also differ from steroidal androgens in its effects due to differences in within-tissue ligand metabolism. The virilizing and androgenic effects of the traditional steroidal androgens like testosterone in skin, hair follicles, and the prostate gland are attributed to high expression of 5α-reductase in these tissues and consequent local conversion and potentiation into more potent androgens. In the case of testosterone, this is via conversion into the 10-fold more potent androgen DHT.
Prior to this, 2D-LC was performed using components from 1D-LC instruments, and would lead to results of varying degrees in both accuracy and precision. The reduced stress on instrumental engineering has allowed for pioneering work in the field and technique of 2D-LC. The purpose of employing this technique is to separate mixtures that one-dimensional liquid chromatography otherwise cannot separate effectively. Two-dimensional liquid chromatography is better suited to analyzing complex mixtures samples such as urine, environmental substances and forensic evidence such as blood. Difficulties in separating mixtures can be attributed to the complexity of the mixture in the sense that separation cannot occur due to the number of different effluents in the compound. Another problem associated with one-dimensional liquid chromatography involves the difficulty associated to resolving closely related compounds. Closely related compounds have similar chemical properties that may prove difficult to separate based on polarity, charge, etc. Two-dimensional liquid chromatography provides separation based on more than one chemical or physical property. Using an example from Nagy and Vekey, a mixture of peptides can be separated based on their basicity, but similar peptides may not elute well. Using a subsequent LC technique, the similar basicity between the peptides can be further separated by employing differences in apolar character.
Dutch investigators believe a criminal organisation from the port city of Rotterdam was involved in this hit. In June 2018, the Dutch government evicted two diplomats from the Iranian embassy and deported them from the country. The two men were members of Iran's intelligence agencies. This case eventually created more tension between the 2 countries.
Only one Ambrosiella (A. cleistominuta from the xyleborine ambrosia beetle Anisandrus maiche) has ever been reported to produce sexual structures, and the rest (including A. roeperi) have been assumed to undergo exclusively clonal reproduction. All Ambrosiella produce translucent, flask-shaped conidiogenous cells (phialides) borne on non-fertile sporodochia (minute, dense cushions of nonreproductive hyphae holding up the fertile tissue). Conidia may arise from these phialides as chains – i.e., new spores are successively pushed out, with the newest growth closest to the original conidiogenous cell – or singly, as an aleurioconidium that ruptures the membrane of the mother cell and then remains a unique, differentiated terminal unit without any subsequent neighbors produced from the phialide. A. roeperi operates only through the latter mechanism, which is distinct from what is reported in A. beaveri, A. trypodendri, and A. hartigii (suggested to use the former, chain-like method).
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.